Department of Bioengineering, University of Pennsylvania, Philadelphia, 19104, USA.
Adv Mater. 2011 Mar 25;23(12):H41-56. doi: 10.1002/adma.201003963. Epub 2011 Mar 10.
Hyaluronic acid (HA), an immunoneutral polysaccharide that is ubiquitous in the human body, is crucial for many cellular and tissue functions and has been in clinical use for over thirty years. When chemically modified, HA can be transformed into many physical forms-viscoelastic solutions, soft or stiff hydrogels, electrospun fibers, non-woven meshes, macroporous and fibrillar sponges, flexible sheets, and nanoparticulate fluids-for use in a range of preclinical and clinical settings. Many of these forms are derived from the chemical crosslinking of pendant reactive groups by addition/condensation chemistry or by radical polymerization. Clinical products for cell therapy and regenerative medicine require crosslinking chemistry that is compatible with the encapsulation of cells and injection into tissues. Moreover, an injectable clinical biomaterial must meet marketing, regulatory, and financial constraints to provide affordable products that can be approved, deployed to the clinic, and used by physicians. Many HA-derived hydrogels meet these criteria, and can deliver cells and therapeutic agents for tissue repair and regeneration. This progress report covers both basic concepts and recent advances in the development of HA-based hydrogels for biomedical applications.
透明质酸(HA)是一种在人体中普遍存在的免疫中性多糖,对许多细胞和组织功能至关重要,已经在临床上使用了三十多年。化学修饰后,HA 可以转化为多种物理形式——粘弹性溶液、软或硬水凝胶、静电纺纤维、无纺网、大孔和纤维状海绵、柔性片材和纳米颗粒流体——用于多种临床前和临床环境。这些形式中的许多都是通过加合/缩合化学或自由基聚合来衍生自侧链反应性基团的化学交联。用于细胞治疗和再生医学的临床产品需要与细胞包封和组织内注射相容的交联化学。此外,可注射的临床生物材料必须满足市场、监管和财务限制,以提供负担得起的产品,这些产品可以获得批准、部署到临床并由医生使用。许多基于 HA 的水凝胶符合这些标准,并可以输送细胞和治疗剂用于组织修复和再生。本进展报告涵盖了用于生物医学应用的基于 HA 的水凝胶的基本概念和最新进展。